The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

According to Precedence Research, the radiopharmaceuticals market size has been estimated at USD 7.51 billion in 2025 and is projected to reach approximately USD 14.44 billion by 2034, growing at a ...

The sector has seen billions in merger and acquisition activity in recent years; a September 2024 analysis by Insight ...

Surufatinib did not provide an OS benefit over placebo, but there was a high rate of crossover from the placebo group to the surufatinib group.

castration-resistant prostate cancer and LUTATHERA ®, the first and only approved radiation treatment for adults with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that can grow in the ...

Patients treated for advanced neuroendocrine tumors (NETs) are at risk of disease progression after existing treatments, and the current options are often dependent on particular disease factors that ...

Woese Institute for Genomic Biology, University of Illinois at Urbana−Champaign, Urbana, Illinois 61801, United States Pancreatic neuroendocrine tumors (PNETs) are rare tumors that are often diagnosed ...

The gut microbiome has emerged as a potential factor in cancer pathogenesis, but its role in non-functioning pituitary neuroendocrine tumors (NF-PitNETs) remains unclear. This study aimed to elucidate ...

The Swiss drugmaker already has two commercial products on the market: Lutathera, indicated for gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and Pluvicto, for metastatic ...

The approval was based on the results of the phase 3 CABINET study, which compared cabozantinib to a placebo in patients with advanced pancreatic neuroendocrine tumors and advanced extrapancreatic ...

MONDAY, March 31, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients with previously treated ...